ライフサイエンスコーパス: SAH

1 SAH did not alter preadipocyte factor 1 (Dlk1) or peroxi

2 SAH increased Rxralpha methylation on a CpG unit (chr2:2

3 SAH is a potent feedback inhibitor of S-adenosylmethioni

4 SAH volume was dichotomised on the Fisher grade.

5 SAH was associated with increased Proteobacteria (SAH 14

6 SAH was defined as an adult height <= 2 standard deviati

7 SAH was presented in 38.46% of patients with VSIAs.

8 SAH-albumin showed the highest albumin oxidative state (

9 SAH-SOS1 peptides bound in a sequence-specific manner to

10 bilized alpha helices of son of sevenless 1 (SAH-SOS1) as prototype therapeutics that directly inhibi

11 pants (HC, n = 24; HDC, n = 20; MAH, n = 10; SAH, n = 24) were studied. HDC had a distinct signature

12 in a 10.1% lifetime incidence of SAH and 183 SAH-related deaths.

13 Among 479 SAH patients, 53 (11%) had in-hospital NCSz.

14 ion of the recombinant mouse myosin VIIa-5IQ-SAH R502P (myoVIIa-sh1) construct.

15 e versa) in the naturally-occurring myosin-6 SAH similarly increased (or decreased) its stability.

16 eurysms, 19 procedure-related deaths, and 65 SAH-related deaths.

17 sible mechanism of methazolamide in C57BL/6J SAH animal model in vivo and in blood-induced primary co

18 oism and mass spectrometry as expected for a SAH domain.

19 th growth hormone, 9.2% (254 of 2,776) had a SAH.

20 erimental evidence that ion pairs exist in a SAH in murine myosin 7a (residues 858-935), but that the

21 +) stores using cyclopiazonic acid abolished SAH-induced eHACSs and restored arteriolar dilation in S

22 alyzed hydrolysis of S-adenosylhomocysteine (SAH) and for sensing adenosine based on the inhibition o

23 ociation of ADK with S-adenosylhomocysteine (SAH) hydrolase (SAHH).

24 lmethionine (SAM) or S-adenosylhomocysteine (SAH) in the catalytic site.

25 S-adenosylhomocysteine (SAH) is a negative regulator of most methyltransferases

26 l and progeny plasma S-adenosylhomocysteine (SAH) levels are both elevated after vitamin deficiency i

27 -362) complexed with S-adenosylhomocysteine (SAH) or 5'-deoxyadenosine (5'-dAdo) and l-methionine (l-

28 e the deamination of S-adenosylhomocysteine (SAH) to S-inosylhomocysteine (SIH).

29 zyme that hydrolyzes S-adenosylhomocysteine (SAH), a product and inhibitor of methyltransferases.

30 creatinine, betaine, S-adenosylhomocysteine (SAH), and S-adenosylmethionine (SAM), and higher percent

31 cocrystallized with S-adenosylhomocysteine (SAH), Formycin A (FMA), and (3R,4S)-4-(4-Chlorophenylthi

32 the reaction product S-adenosylhomocysteine (SAH), or the SAH analog sinefungin (SFG).

33 of these nutrients, S-adenosylhomocysteine (SAH), S-adenosylmethionine (SAM), homocysteine, cysteine

34 pable of hydrolysing S-adenosylhomocysteine (SAH).

35 that responds to the S-adenosylhomocysteine (SAH).

36 ed the role of mitophagy following 48h after SAH injury in rats.

37 ion, eNOS activity and NO availability after SAH.

38 asated erythrocytes from CSF into CLNs after SAH, while suggesting that modulating this draining may

39 y and cardiac complications are common after SAH, and are associated with an increased risk of mortal

40 ediates acute microvessel constriction after SAH possibly by hemoglobin suppressing NO/cGMP signaling

41 aring extravasated erythrocytes in CSF after SAH remains unclear.

42 ammatory response and secondary damage after SAH and the underlying mechanisms of action.

43 high-amplitude Ca(2+) signals (eHACSs) after SAH that were not observed in endfeet from unoperated an

44 ATX administered 4 h after SAH ameliorated cerebral inflammation, brain edema, and

45 cyte trafficking at both 24 h and 48 h after SAH, along with an improvement in neurologic outcome.

46 arkedly increased in microglia at 24 h after SAH, with consequent increases in the downstream molecul

47 yte trafficking, during the first 48 h after SAH.

48 ffective elimination of blood and heme after SAH that otherwise leads to neuronal injury and cognitiv

49 Initiation of CO inhalation after SAH rescued the absence of microglial HO-1 and reduced i

50 nt manifestation of early brain injury after SAH and a predictor of death or poor functional outcome

51 pathophysiology of early brain injury after SAH is still unclear.

52 ry response and secondary brain injury after SAH, primarily by increasing sirtuin 1 levels and inhibi

53 aneurysm treatment and quality of life after SAH influenced the preferred screening strategy.

54 atics of CLNs and meningeal lymphatics after SAH.

55 in the regulation of microcirculation after SAH.

56 modified Rankin Scale 4-6 at 3 months after SAH.

57 DCI, functional outcome, and mortality after SAH, independent of clinical and radiographic markers.

58 A common complication observed after SAH is the development of delayed cerebral ischemia at s

59 effectively analyze cognitive outcomes after SAH.

60 suggest that exposure to excess oxygen after SAH may represent a modifiable factor for morbidity and

61 obins penetrated into brain parenchyma after SAH.

62 The postoperative ICU period after SAH is associated with a significant morbidity and morta

63 The study of brain nerve protection after SAH is of great significance.

64 ng and the risk of aneurysm rebleeding after SAH.

65 ated to poor acute neurological status after SAH and predicts future ischaemia and worse functional o

66 arly goal-directed hemodynamic therapy after SAH has recently been shown to improve clinical outcomes

67 Thus, after SAH, signaling events that normally lead to vasodilation

68 s (CD45dimCD11b +) increased over time after SAH.

69 ients at risk for developing vasospasm after SAH.

70 Early worsening after SAH occurs in 35% of patients, is predicted by clot burd

71 ay offer therapeutic approaches to alleviate SAH severity.

72 The addition of adenosine to an SAH solution resulted in the inhibition of SAHH activity

73 ermore, by achieving this flexibility via an SAH domain, the CPC avoids a need for dimerization (requ

74 , 95% CI (- 0.900, - 0.412), p < 0.0001) and SAH (beta = 0.371, 95% CI (0.071, 0.672), p = 0.017) wer

75 eased Proteobacteria (SAH 14% vs. HDC 7% and SAH vs. HC 2%, P = 0.20 and 0.01, respectively).

76 ial taxa did not distinguish between MAH and SAH (PERMANOVA P = 0.785).

77 prophylactic IA treatment and mortality and SAH deaths prevented.

78 -MB-T8 . Hg(2+) probe combining the SAHH and SAH systems was used for sensitive and selective detecti

79 methods to discover and characterize SAM and SAH binding proteins using fluorescent CCs.

80 itches strongly discriminate between SAM and SAH, the SAM/SAH riboswitch responds to both ligands wit

81 nto 4 groups: Sham, SAH, SAH+VDAC1siRNA, and SAH+RAPA.

82 ion in 609 consecutively admitted aneurysmal SAH patients.

83 on criteria were age >/=18 years, aneurysmal SAH, endotracheal intubation with mechanical ventilation

84 The mean interval between SAH and PPV was 4.4 months (range, 3-5 months).

85 These data indicate a causal link between SAH-induced eHACSs and inversion of NVC.

86 ent methylases that are able to tightly bind SAH.

87 -ammonium of K9 positioned adjacent to bound SAH.

88 tive site architecture of viperin with bound SAH (a SAM analog) or 5'-dAdo and l-Met (SAM cleavage pr

89 Hypomethylation stress, caused by SAH accumulation, inhibits the formation of the methylat

90 ated DNA, substrate H3 peptide, and cofactor SAH, thereby defining the spatial positioning of the SRA

91 In conclusion, SAH did not affect adipogenesis per se but altered adipo

92 is the occurrence of nontraumatic convexity SAH unaccounted for by aneurysmal rupture.

93 After demonstrating SAH-dependent photo-crosslinking of the CC to these prot

94 young flies and suppression of age-dependent SAH accumulation lead to increased life span.

95 Sinus thrombosis presenting as diffuse SAH is extremely rare, as is showcased in this report.

96 solated stable single alpha-helical domains (SAH).

97 In addition, during SAH lymph flow is increased but without significant lymp

98 The elevated SAH level in the cell dissociates SahR from its DNA oper

99 brovascular pathology following experimental SAH.

100 isorder, lower Hunt-Hess grade, lower Fisher SAH group, and the presence of bilateral arterial narrow

101 disease, lower Hunt-Hess grade, lower Fisher SAH group, higher number of affected arteries, and the p

102 orality, fluctuation of cerebral blood flow, SAH grade, and cerebral vasospasm of SAH mice.

103 findings suggest that inflammation following SAH is associated with poor outcome and that this effect

104 AC1siRNA worsened the brain injury following SAH.

105 neurons were reduced by Rapamycin following SAH injury.

106 between the inflammatory response following SAH and in-hospital NCSz studying clinical (systemic inf

107 iated with a proinflammatory state following SAH as reflected in clinical symptoms and serum biomarke

108 f heightened leukocyte trafficking following SAH, induced via endovascular perforation of the anterio

109 lusion, mitophagy induced by VDAC1 following SAH injury may in fact play a significant role in neurop

110 s exceeded that of commercial antibodies for SAH and proved critical to cellular applications, as we

111 Our study aimed to quantify risk factors for SAH or growth hormone deficiency among CCS.

112 0.24]) were all independent risk factors for SAH.

113 strategy, but retained full selectivity for SAH over its close structural analogue, the highly abund

114 it provides potential as a novel therapy for SAH.

115 after stimulation with purified albumin from SAH patient plasma.

116 Primary blood mononuclear cells from SAH patients and elective aneurysm controls were analyze

117 Furthermore, SAH-induced oxidative stress creates a proinflammatory a

118 risk of subsequent subarachnoid haemorrhage (SAH) by follow-up on intensive medical treatment, with g

119 was diagnosed with subarachnoid haemorrhage (SAH) in the region of the previously treated LMCA aneury

120 gical intensity of subarachnoid haemorrhage (SAH) was evaluated by using the Hunt-Hess and Fisher sca

121 c attack (TIA) and subarachnoid haemorrhage (SAH).

122 a risk factor for subarachnoid haemorrhage (SAH).

123 s frequently after subarachnoid haemorrhage (SAH).

124 aired growth, leading to small adult height (SAH).

125 Highly charged, single alpha-helical (SAH) domains contain a high percentage of Arg, Lys, and

126 Highly charged single alpha-helical (SAH) domains, consisting of a high percentage (>75%) of

127 disordered except for a single alpha-helix (SAH) at the N terminus and a short nascent helix, LH, fl

128 rvivin and Borealin, the single alpha-helix (SAH) domain of INCENP supports CPC localization to chrom

129 approximately 32-nm-long single alpha-helix (SAH) domain.

130 Single alpha-helix (SAH) domains are rich in charged residues (Arg, Lys, and

131 important in stabilizing single alpha-helix (SAH) domains in solution.

132 sms (IA) and suffer subarachnoid hemorrhage (SAH) at younger ages than the general population.

133 Subarachnoid hemorrhage (SAH) carries a 50% mortality rate.

134 Aneurysmal subarachnoid hemorrhage (SAH) is a potentially devastating clinical problem.

135 lices obtained from subarachnoid hemorrhage (SAH) model rats.

136 study of aneurysmal subarachnoid hemorrhage (SAH) patients, we explored the link between the inflamma

137 Subarachnoid hemorrhage (SAH) results in significant nerve dysfunction, such as h

138 esenting symptom of subarachnoid hemorrhage (SAH) that is presumed to result from transient intracran

139 Subarachnoid hemorrhage (SAH) usually results from ruptured aneurysm, but how lea

140 t of patients after subarachnoid hemorrhage (SAH), especially with regards to hemodynamic management,

141 atement: Aneurysmal subarachnoid hemorrhage (SAH)--strokes involving cerebral aneurysm rupture and re

142 ences of aneurysmal subarachnoid hemorrhage (SAH).

143 ity of nontraumatic subarachnoid hemorrhage (SAH).

144 ly period following subarachnoid hemorrhage (SAH).

145 the pathogenesis of subarachnoid hemorrhage (SAH).

146 is in patients with subarachnoid hemorrhage (SAH).

147 the progression of subarachnoid hemorrhage (SAH).

148 processes including subarachnoid hemorrhage (SAH).

149 Severe alcoholic hepatitis (SAH) is often a progressive disease with high mortality

150 ating albumin in severe alcoholic hepatitis (SAH) patients and their contribution to neutrophil activ

151 patitis (MAH) or severe alcoholic hepatitis (SAH) was compared with healthy controls (HCs) and heavy

152 in patients with severe alcoholic hepatitis (SAH), but little information is available on how to pred

153 in patients with severe alcoholic hepatitis (SAH), but little information is available on how to pred

154 High SAH levels were significantly associated with low H19 me

155 describe a suite of S-adenosyl homocysteine (SAH) photoreactive probes and their application in chemi

156 ethyl donor product S-adenosyl-homocysteine (SAH) and its ortholog scTrm10 from Saccharomyces cerevis

157 d in high levels of S-adenosyl-homocysteine (SAH) and low levels of S-adenosyl-methionine (SAM).

158 via methylation to S-adenosyl-homocysteine (SAH), which accumulates during aging.

159 lex with cofactor S-adenosyl-L-homocysteine (SAH) and six substrate peptides, respectively, and revea

160 The affinity of S-adenosyl-l-homocysteine (SAH) for SAM binding proteins was used to design two SAH

161 nt biosensors for S-adenosyl-l-homocysteine (SAH) that provide a direct "mix and go" activity assay f

162 U4G5U6U7-3'), and S-adenosyl-l-homocysteine (SAH), the by-product of the methylation reaction.

163 ) is converted to S-adenosyl-l-homocysteine (SAH).

164 cteristic of systemic arterial hypertension (SAH) and an early marker of atherosclerosis.

165 mouse model and a new severe acute hypoxia (SAH) mouse model of DWMI activates the initial step of t

166 In SAH patients, exposure to hyperoxia was associated with

167 and plasma oxidative stress were assessed in SAH patients (n = 90), alcoholic cirrhosis patients (n =

168 to a substantial degree of cooperativity in SAH stability.

169 d eHACSs and restored arteriolar dilation in SAH brain slices to two mediators of NVC (a rise in endf

170 al edema, and improves cognitive function in SAH mice as well as offers neuroprotection in blood- or

171 crocirculation, and neurological function in SAH rats.

172 Expression of the above-mentioned genes in SAH-albumin-stimulated healthy neutrophils was comparabl

173 ced oxidative protein product) was higher in SAH versus alcoholic cirrhosis patients and healthy cont

174 and intracellular ROS levels were highest in SAH-albumin-treated neutrophils (P < 0.05).

175 risk factors for development of infection in SAH.

176 romotes oxidative stress and inflammation in SAH patients through activation of neutrophils.

177 us toll-like receptors were overexpressed in SAH neutrophils compared to healthy neutrophils (P < 0.0

178 dings identify astrocytes as a key player in SAH-induced decreased cortical blood flow.

179 eased on Cebpalpha and Rxralpha promoters in SAH-treated adipocytes, consistent with the reduction in

180 Thus, the INCENP SAH could act as a flexible "dog leash," allowing Aurora

181 The INCENP SAH domain also mediates INCENP's microtubule binding, w

182 myosin 10, our data suggest that the INCENP SAH might stretch up to approximately 80 nm under physio

183 We propose that increased SAH levels and inflammation affect widespread epigenetic

184 enables cells to preserve SAM by increasing SAH to limit SAM consumption by methyltransferase enzyme

185 tures were exposed to oxyhemoglobin to mimic SAH in vitro.

186 Management options of steroid nonresponsive SAH (day 7 Lille score > 0.45) are limited.

187 ted day-90 outcomes in steroid nonresponsive SAH.

188 The mechanism of action of SAH-SOS1 peptides was demonstrated by sequence-specific

189 There are few reported cases of SAH secondary to dural sinus thrombosis; however most of

190 n was performed, but due to complications of SAH the woman eventually died.

191 Gene expression of SAH neutrophils was analyzed and compared to gene expres

192 BOX concentrations in cerebrospinal fluid of SAH patients compared with control subjects.

193 ere, we review the structure and function of SAH domains, as well as the tools to identify them in na

194 SAHH catalyzed the hydrolysis of SAH to produce homocysteine.

195 ng resulted in a 10.1% lifetime incidence of SAH and 183 SAH-related deaths.

196 .1% (95% CI 4.8 to 5.5) and the incidence of SAH was 4.6 (95% CI 1.9 to 11.0) per 1000 person-years.

197 we were able to monitor in vivo increase of SAH levels upon chemical inhibition of MTAN using flow c

198 ced in tx-j mice with consequent increase of SAH levels.

199 lowing endovascular perforation induction of SAH in mice, a heavily-utilized model.

200 data may shed new light on the management of SAH patients.

201 ary cortical neuron (PCNs) cellular model of SAH in vitro.

202 lymphatics are depleted in a mouse model of SAH, the degree of erythrocyte aggregation in CLNs is si

203 Here, using a murine model of SAH, we demonstrated that expression of the inducible HO

204 ty patients (40.4%) reported LOC at onset of SAH.

205 validation, we used a control population of SAH patients from the CONSCIOUS-1 study (n = 413).

206 rine 3T3-L1 preadipocytes in the presence of SAH impaired both basal and induced glucose uptake as we

207 However, the risk of SAH on intensive medical treatment and guideline-based m

208 linked with significantly increased risk of SAH.

209 ut pituitary irradiation increased the RR of SAH by 4.62 (95% CI, 2.77 to 7.72).

210 f rare but clinically significant sources of SAH.

211 A subset of SAH domains contain a characteristic ER/K motif, compose

212 een the sulfonium of SAM or the thioether of SAH.

213 Prednisolone is advocated for treatment of SAH, but can increase susceptibility to infection.

214 e advances in the diagnosis and treatment of SAH, outcome remains unfavorable.

215 rovide evidence for the potential utility of SAH-SOS1 peptides in neutralizing oncogenic KRAS in huma

216 d flow, SAH grade, and cerebral vasospasm of SAH mice.

217 During mean follow-up of 4.5 years, only one SAH occurred: 2.3 (95% CI 0.3 to 16.6) per 1000 person-y

218 appear to play a major role in either MCH or SAH-induced DWMI and is therefore not a likely target fo

219 SR has no detectable effect on either MCH or SAH-induced DWMI.

220 cement of the ISR does not ameliorate MCH or SAH-induced DWMI.

221 t conformations, and that addition of SAM or SAH shifts the population into a stable state that likel

222 ted Cap-0 analog m(7)GpppA and either SAM or SAH.

223 in complex with an H3K36M peptide and SAM or SAH.

224 Upon binding Nip100, only Pac11 SAH residues make direct protein-protein interactions, b

225 Endovascular perforation SAH rat model, brain slices and cultured pericytes were

226 tment with LJP-1586 was initiated at 6h post-SAH.

227 Experiments focused on the initial 48 h post-SAH and sought to establish whether blockade of vascular

228 leukocyte trafficking at 24 h and 48 h post-SAH were examined.

229 e accumulation of the homocysteine precursor SAH, suppresses GPx-1 expression and leads to inflammato

230 ties and unfolding behavior of the predicted SAH domain from myosin-10 were characterized.

231 as associated with increased Proteobacteria (SAH 14% vs. HDC 7% and SAH vs. HC 2%, P = 0.20 and 0.01,

232 2016 in patients with histologically proven SAH, nonresponsive to 40 mg/day of prednisolone were ran

233 The expressed and purified SAH domain was highly helical, melted non-cooperatively,

234 identify predictors that differentiate RCVS-SAH from aSAH and cSAH.

235 Predictors differentiating RCVS-SAH from aSAH were younger age, chronic headache disorde

236 Predictors differentiating RCVS-SAH from cSAH were younger age, female sex, prior hypert

237 Consecutive patients with RCVS-SAH (n = 38), aSAH (n = 515), or cSAH (n = 93) whose con

238 e randomly divided into 4 groups: Sham, SAH, SAH+VDAC1siRNA, and SAH+RAPA.

239 nes related to liver injury, levels of SAHH, SAH, DNA methyltransferases genes (Dnmt1, Dnmt3a, Dnmt3b

240 nM) and was reusable for detecting the SAHH/SAH system.

241 ine, MMA, metabolites of 1C metabolism (SAM, SAH) and anthropometry were measured.

242 interesting positive association between SAM/SAH ratio and high H19 methylation levels was detected a

243 ave determined crystal structures of the SAM/SAH riboswitch bound to SAH, SAM and other variant ligan

244 ly discriminate between SAM and SAH, the SAM/SAH riboswitch responds to both ligands with similar app

245 s were randomly divided into 4 groups: Sham, SAH, SAH+VDAC1siRNA, and SAH+RAPA.

246 osticate long-term outcome after spontaneous SAH in a multidimensional manner.

247 secutively treated patients with spontaneous SAH who were part of a prospective observational cohort

248 We studied SAH patients from 2 independent cohorts.

249 Our findings demonstrate that SAH accumulation in endothelial cells suppresses the exp

250 Here, we provide evidence that SAH-induced changes in astrocyte Ca(2+) signaling lead t

251 Taken together, these data suggest that SAH accumulation in endothelial cells can induce tRNA(Se

252 all enzymes required for the SAM cycle: the SAH hydrolase AhcY, the methionine biosynthesis enzymes

253 This enables the SAH domain to act as a constant force spring in the mech

254 ted phosphorylation of segments flanking the SAH domain.

255 r 1,619 consecutive patients enrolled in the SAH outcome project July 1996 to March 2014.

256 The microtubule-binding capacity of the SAH domain is important for mitotic arrest in conditions

257 C, supporting the idea that the role of the SAH helix is to act as an extension of the myosin-VI lev

258 two noncanonical Drosophila homologs of the SAH hydrolase Ahcy (S-adenosyl-L-homocysteine hydrolase

259 product S-adenosylhomocysteine (SAH), or the SAH analog sinefungin (SFG).

260 rce spectroscopy experiments showed that the SAH domain unfolded at very low forces (<30 pN) without

261 lecular dynamics simulations showed that the SAH domain unfolds progressively as the length is increa

262 We further demonstrate that the SAH probes can enrich MT-associated proteins and be used

263 These SAH domains provide unique structural features essential

264 tructures of the SAM/SAH riboswitch bound to SAH, SAM and other variant ligands at high resolution.

265 icutes abundance declined from HDC to MAH to SAH (63% vs. 53% vs. 48%, respectively; P = 0.09, HDC vs

266 rievable stent to treat vasospasm related to SAH due to an aneurysm in four neurointerventional radio

267 hyl sinks to enable the conversion of SAM to SAH.

268 or middle cerebral artery (MCA) secondary to SAH due to an aneurysm treated with endovascular angiopl

269 cacious treatment for vasospasm secondary to SAH due to an aneurysm, improving CTT and stenosis.

270 of active caspase-3 in methazolamide-treated SAH mice comparing with vehicle-treated SAH animals.

271 ated SAH mice comparing with vehicle-treated SAH animals.

272 SAM binding proteins was used to design two SAH-derived capture compounds (CCs).

273 r altered endfoot Ca(2+) signaling underlies SAH-induced inversion of NVC.

274 emic medical center (the Columbia University SAH Outcomes Project or SHOP).

275 of more than 200 angstrom for the myosin VI SAH domain.

276 53% vs. 48%, respectively; P = 0.09, HDC vs. SAH).

277 n model that applied to the whole group were SAH, trimethylamine, choline, and female sex, whereas pl

278 Animals in which SAH was induced exhibited reduced acute functional capac

279 later the woman was once again admitted with SAH - an enlarged LMCA aneurysm was observed and immedia

280 e variant (HpMTAN-D198N) cocrystallized with SAH.

281 ated healthy neutrophils was comparable with SAH patient neutrophils, except for genes associated wit

282 rom Saccharomyces cerevisiae in complex with SAH.

283 functional binding activity correlated with SAH-SOS1 cytotoxicity in cancer cells expressing wild-ty

284 ion remain controversial in individuals with SAH.

285 in the cerebrospinal fluid of patients with SAH compared to controls.

286 : Approximately one-quarter of patients with SAH do not respond to corticosteroid therapy.

287 Patients with SAH given prednisolone are at greater risk for developin

288 ative human data revealed that patients with SAH have markedly higher HO-1 activity in cerebrospinal

289 increased 90-day mortality in patients with SAH treated with prednisolone, independent of model for

290 ctive, hypothesis-driven study patients with SAH underwent MRI within 0-3 days of ictus (prior to vas

291 In 61 patients with SAH, 131 MRI were performed.

292 Of the 430 patients with SAH, 132 received steroid therapy.

293 In patients with SAH, there is a significant increase in albumin oxidatio

294 e (400 mg 3 times each day) in patients with SAH.

295 e used to select therapies for patients with SAH.

296 in the cerebrospinal fluid of patients with SAH.

297 of delayed ischemic deficit in patients with SAH.

298 We enrolled 1312 consecutive patients with SAH; 643 (49%) had premorbid HTN.

299 main bound to H3K36M or H3K36I peptides with SAH (S-adenosylhomocysteine).

300 eractions of the proteins COMT and SAHH with SAH-CC with biotin used in conjunction with streptavidin